在HR+/HER2-乳腺癌患者的Palbociclib治疗持久性:一个现实世界的研究
Alejandro Valcuende-Rosique1, Dolores Rosique-Robles2, Aina Iranzo Sabater3
1Pharmacy Department, Hospital Padre Jofre, Valencia, Spain.
概括
这项研究发现,在现实环境下,Palbociclib在高级HR+/HER2-乳腺癌患者中具有很高的坚持性和持久性. 治疗中止率与临床试验相当,疾病进展是主要原因.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床实践 临床实践
背景情况:
- 先进的HR+/HER2-乳腺癌需要有效的长期治疗.
- 帕尔博西克利布是用于这一患者群体的向治疗.
- 关于palbociclib坚持和持续性的真实世界数据至关重要.
研究的目的:
- 为了评估对palbociclib治疗的坚持和持续性.
- 评估palbociclib在晚期HR+/HER2-乳腺癌中的实际临床实践结果.
- 为了确定停止治疗的原因.
主要方法:
- 使用电子医疗记录进行观察性,回顾性研究.
- 包括晚期HR+/HER2-乳腺癌发病的患者.
- 通过药物占有率 (MPR) 评估坚持性,通过卡普兰-梅尔法评估持久性.
主要成果:
- 治疗坚持度很高 (92.7%的MPR≥80%),中位持续时间为40.9个月.
- 坚持率:83.2%在6个月,72.2%在12个月,57.9%在24个月.
- 在47.6%的患者中断治疗,主要是由于疾病进展 (37.8%) 或毒性 (9.8%).
结论:
- 帕尔博西克利布在现实世界临床实践中表现出高度的坚持和坚持.
- 停药率与以前临床试验的发现一致.
- 中性和贫血是观察到的最常见的不良事件.
更多相关视频
10:38Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Published on: December 16, 2022
2.7K
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.6K
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648
